Exacerbation (treatment in next 3y) | |||
---|---|---|---|
OR | 95 % CI | p | |
Num. Of visits 2009 (Standard < 25v) | 0.001 | ||
25–50 | 1.64 | (1.17 – 2.29) | 0.004 |
> 50 | 2.95 | (1.25 – 6.94) | 0.013 |
Gender (female) | 1.46 | (1.04 – 2.04) | 0.028 |
Exacerbation | 7.44 | (3.77 – 14.70) | 0.001 |
INT: Female * Age (mean 68y) | 0.96 | (0.93 – 0.99) | 0.003 |
Age (mean 68y) | 1.01 | (1,00 – 1.03) | 0.087 |
Gold severity grade (severe or very severe) | 1.57 | (1.01 – 2.45) | 0.046 |
2009 influenza vaccine | 2.00 | (1.12 – 3.58) | 0.019 |
23-valent Pneumococcal vaccine | 1.82 | (1.00 – 3.29) | 0.049 |
INT: 2009 influenza vaccine * Pneumococcal | 0.46 | (0.20 - 1.02) | 0.055 |
Derivation | |||
Hosmer & Lemeshow | 1.10 | 0.997 | |
AUC ROC | 0.71 | (0.68 – 0.74) | < 0.001 |
Validation | |||
Hosmer & Lemeshow | 41.00 | <0.001 | |
AUC ROC | 0.69 | (0.64 – 0.74) | <0.001 |